Caricamento...
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countr...
Salvato in:
| Pubblicato in: | Clin Kidney J |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295603/ https://ncbi.nlm.nih.gov/pubmed/30581563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy089 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|